Efficacy and safety of infliximab or adalimumab, versus abatacept, in patients with rheumatoid arthritis: ATTEST–AMPLE network randomized trial

Author: Christensen Robin   Tarp Simon   Furst Daniel E   Kristensen Lars E   Bliddal Henning  

Publisher: Future Medicine

ISSN: 1758-4272

Source: International Journal of Clinical Rheumatology, Vol.8, Iss.6, 2013-12, pp. : 647-655

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Our objective was to assess the efficacy of infliximab, adalimumab and abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate. The purpose of this type of analysis is to combine evidence from direct and indirect sources into one overall objective. The meta-data set included results from the ATTEST and AMPLE studies. Major outcomes concerned the benefits and harm after 1 year on therapy; coprimary outcomes patients achieving a 50% response on the ACR improvement criteria, extracted from the papers, and the number of withdrawals related to adverse events, respectively. Statistical analyses were based on mixed-effects logistic regression, using an arm-based, random-effects model respecting randomization within each study. Following indirect comparisons across all three groups, we conclude that infliximab, at the recommended dose, is less efficacious than abatacept and potentially also adalimumab, and that adalimumab and abatacept are approximately equivalent both in terms of benefit and short-term harm assessment (up to 1 year).

Related content